FHTX Foghorn Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FHTX

Price (delayed)

$3.87

Market cap

$229.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.98

Enterprise value

$202.84M

?
Relative Growth: Rel. Growth: 83
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 31
Highlights
The company's revenue has surged by 52% YoY and by 30% QoQ
FHTX's gross profit has surged by 52% year-on-year and by 30% since the previous quarter
The company's debt has surged by 82% YoY and by 2.6% QoQ
The equity has contracted by 6% from the previous quarter and by 6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://foghorntx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of FHTX

FHTX stock price

How has the Foghorn Therapeutics stock price performed over time
Intraday
-8.73%
1 week
-7.19%
1 month
-45.26%
1 year
-22.75%
YTD
-28.33%
QTD
-20.7%

Financial performance

How have Foghorn Therapeutics's revenue and profit performed over time
Revenue
$36.74M
Gross profit
$36.74M
Operating income
-$74.39M
Net income
-$64.58M
Gross margin
100%
Net margin
-175.8%
The company's revenue has surged by 52% YoY and by 30% QoQ
FHTX's gross profit has surged by 52% year-on-year and by 30% since the previous quarter
FHTX's operating margin is up by 47% YoY and by 34% QoQ
The company's net margin rose by 44% YoY and by 34% QoQ

Price vs fundamentals

How does FHTX's price correlate with its fundamentals

Growth

What is Foghorn Therapeutics's growth rate over time

Valuation

What is Foghorn Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
7.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.52
Foghorn Therapeutics's EPS has increased by 18% YoY and by 16% from the previous quarter
The equity has contracted by 6% from the previous quarter and by 6% YoY
FHTX's P/S is 90% lower than its 5-year quarterly average of 81.5 and 27% lower than its last 4 quarters average of 11.2
The company's revenue has surged by 52% YoY and by 30% QoQ

Efficiency

How efficient is Foghorn Therapeutics business performance
FHTX's return on invested capital has dropped by 54% year-on-year but it is up by 21% since the previous quarter
Foghorn Therapeutics's ROS has increased by 44% YoY and by 34% from the previous quarter
The ROA has grown by 12% from the previous quarter but it has contracted by 11% YoY

Dividends

What is FHTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FHTX.

Financial health

How did Foghorn Therapeutics financials performed over time
Foghorn Therapeutics's total assets is 28% lower than its total liabilities
FHTX's quick ratio is up by 29% year-on-year and by 16% since the previous quarter
The current ratio has grown by 28% YoY and by 15% from the previous quarter
The company's debt is 153% higher than its equity
The company's debt has surged by 82% YoY and by 2.6% QoQ
The debt to equity has shrunk by 71% YoY but it is up by 3.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.